ASX:SPL Starpharma (SPL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Starpharma Stock (ASX:SPL) 30 days 90 days 365 days Advanced Chart Get Starpharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume351,391 shsAverage VolumeN/AMarket CapitalizationA$43.90 millionP/E RatioN/ADividend Yield9.30%Price TargetN/AConsensus RatingN/A Company Overview Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia. Read More Receive SPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Starpharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPL Stock News HeadlinesStarpharma Secures $3.7 Million R&D Tax Incentive to Boost Biotechnology AdvancementsAugust 27, 2025 | tipranks.comStarpharma Reports Revenue Decline but Adjusted Growth Amid R&D InvestmentsAugust 26, 2025 | tipranks.comIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.September 10 at 2:00 AM | American Alternative (Ad)Starpharma Releases 2025 Corporate Governance StatementAugust 26, 2025 | tipranks.comHealth Check: Pro Medicus banks the profits as customers go the ‘full stack’August 14, 2025 | msn.comStarpharma’s DEP® SN38 Shows Promising Cancer Treatment ResultsNovember 21, 2024 | markets.businessinsider.comStarpharma Holdings: Advancing Clinical Pathways and GrowthOctober 31, 2024 | markets.businessinsider.comStarpharma Director Increases Shareholding SignificantlyOctober 24, 2024 | markets.businessinsider.comSee More Headlines SPL Stock Analysis - Frequently Asked Questions How were Starpharma's earnings last quarter? Starpharma Holdings Limited (ASX:SPL) posted its earnings results on Wednesday, February, 27th. The company reported ($0.02) earnings per share for the quarter. Starpharma had a negative trailing twelve-month return on equity of 26.10% and a negative net margin of 91.45%. What other stocks do shareholders of Starpharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Starpharma investors own include Starpharma (SPHRY), Allena Pharmaceuticals (ALNA), Aurora Cannabis (ACBFF), Ampliphi Biosciences (APHB), AstraZeneca (AZN), Arbutus Biopharma (ABUS) and AcelRx Pharmaceuticals (ACRX). Company Calendar Last Earnings2/27/2019Today9/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:SPL CIKN/A Webwww.starpharma.com Phone+61-3-85322700FaxN/AEmployees45Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$8.16 million Net Margins-91.45% Pretax MarginN/A Return on Equity-26.10% Return on Assets-11.48% Debt Debt-to-Equity Ratio12.55 Current Ratio4.94 Quick Ratio5.65 Sales & Book Value Annual SalesA$9.76 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.42 Book ValueA$0.07 per share Price / BookN/AMiscellaneous Outstanding Shares417,370,000Free FloatN/AMarket CapA$43.90 million OptionableNot Optionable Beta0.77 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (ASX:SPL) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Starpharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Starpharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.